Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nova Leap HealthNVLPF 50 EV-to-EBITDA is 16.06 as of Jul. 15, 2026, which is 7% above its 10-year median of 14.97. GuruFocus rates NVLPF with a GF Score™ of 50/100 and a GF Value™ of $0.22 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 507 Healthcare Providers & Services companies, Nova Leap Health ranks worse than 69.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nova Leap Health's enterprise value is $24.59 Mil.
Nova Leap Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1.53 Mil. Therefore, Nova Leap Health's EV-to-EBITDA for today is 16.06.
The historical rank and industry rank for Nova Leap Health's EV-to-EBITDA or its related term are showing as below:
NVLPF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5752.2 Med: 14.97 Max: 202.09
Current: 16.51
During the past 10 years, the highest EV-to-EBITDA of Nova Leap Health was 202.09. The lowest was -5752.20. And the median was 14.97.
NVLPF's EV-to-EBITDA is ranked worse than 69.03% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 10.89
vs NVLPF: 16.51
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Nova Leap Health (OTCPK:NVLPF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nova Leap Health's PE Ratio (TTM) for today is calculated as:
Nova Leap Health's share price for today is $0.26.
Nova Leap Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Nova Leap Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Nova Leap Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Leap Health EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nova Leap Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nova Leap Health's EV-to-EBITDA falls into.
Nova Leap Health's current Enterprise Value is $24.59 Mil.
Nova Leap Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Leap Health (NVLPF) has a EV-to-EBITDA of 16.06 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nova Leap Health. This is near median its historical median of 14.97. According to the industry distribution chart, Nova Leap Health ranks #350 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 69%.
Is Nova Leap Health's EV-to-EBITDA too high?
Nova Leap Health's current EV-to-EBITDA of 16.06 is near median its 10-year median of 14.97. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.89. Nova Leap Health's value of 16.06 is 47.5% above this industry median. Based on the distribution chart, Nova Leap Health ranks #350 out of 507 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Nova Leap Health has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nova Leap Health's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Nova Leap Health ranks #350 out of 507 companies for EV-to-EBITDA. This places Nova Leap Health in the lower half of its industry. The industry median EV-to-EBITDA is 10.89. Nova Leap Health's value of 16.06 is 47.5% above this benchmark. While the company's 10-year median is 14.97 vs. the industry median of 10.89, Nova Leap Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.89, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nova Leap Health's current EV-to-EBITDA of 16.06 is 47.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nova Leap Health. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Leap Health's current EV-to-EBITDA is 16.06, which is near median its own 10-year median of 14.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Leap Health stock overvalued right now?
Based on GuruFocus' analysis, Nova Leap Health (NVLPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.22, compared to a current price of $0.26 — trading 18.2% above its estimated fair value. The current EV-to-EBITDA is 16.06, which is near median its 10-year median of 14.97 and 47.5% above the Healthcare Providers & Services industry median of 10.89. Nova Leap Health's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Nova Leap Health (NVLPF), the current EV-to-EBITDA is 16.06 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Leap Health (NVLPF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Leap Health stock appears to be overvalued.
The current stock price of $0.26 is trading 18.2% above its estimated GF Value™ of $0.22.
GuruFocus considers Nova Leap Health to be Modestly Overvalued.
Key valuation signals for NVLPF:
EV-to-EBITDA: 16.06 (near median its 10-year median of 14.97)
GF Value™: $0.22 vs. price of $0.26 (18.2% above fair value)
Industry Position: 47.5% above the Healthcare Providers & Services median (#350 of 507)
No single metric tells the full story. See the NVLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Leap Health Corp operates in the healthcare industry. The company is a provider of home and home health care services to clients..The principal business activities of the company and its subsidiaries are to provide skilled and non-medical home care to clients. Its service offerings include meal preparation, housekeeping, transportation, personal care, and medication reminders. Its segments comprise Canadian and U.S. operations. The company derives a majority of its revenue from the United States.
50GF Score
Get the complete analysis for NVLPF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVLPF has been successfully added to your 
